Scientists from the Universities of Antwerp and Hasselt in Belgium predict that a temporary rise in shingles cases will dominate 31- to 40-year-olds, which is a younger age group than previously predicted. This age group will not likely develop the most serious shingles symptoms.
The scientists also developed a new model on the length of time re-exposure to chickenpox boosts immunity to shingles based on real immunological and virological data from individuals. Previously, the effect was estimated to last up to 20 years, but the model shows it only lasts two years.
“We were surprised to find that re-exposure to chickenpox is beneficial for so few years and also that the most pronounced effect of vaccination on increasing cases of shingles is in younger adults,” said lead author Benson Ogunjimi, MD, PhD. “Our findings should allay some fears about implementing childhood chickenpox vaccination.”
More articles on vaccines:
15 recent stories, studies on vaccines
Study determines which states have the most, least effective vaccine exemption policies
Psychologists explore how best to convince vaccine skeptics to reconsider
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
